184 related articles for article (PubMed ID: 26903171)
1. The prospective IQ-CSRC trial: A prototype early clinical proarrhythmia assessment investigation for replacing the ICH E14 thorough QTc (TQT) study.
Cavero I; Holzgrefe H; Clements M
J Pharmacol Toxicol Methods; 2016; 80():1-8. PubMed ID: 26903171
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Effect of 5 QT-Positive Drugs on the JTpeak Interval - An Analysis of ECGs From the IQ-CSRC Study.
Darpo B; Benson C; Brown R; Dota C; Ferber G; Ferry J; Jarugula V; Keirns J; Ortemann-Renon C; Pham T; Riley S; Sarapa N; Ticktin M; Zareba W; Couderc JP
J Clin Pharmacol; 2020 Jan; 60(1):125-139. PubMed ID: 31378962
[TBL] [Abstract][Full Text] [Related]
3. Implications of the IQ-CSRC Prospective Study: Time to Revise ICH E14.
Darpo B; Garnett C; Keirns J; Stockbridge N
Drug Saf; 2015 Sep; 38(9):773-80. PubMed ID: 26162419
[TBL] [Abstract][Full Text] [Related]
4. The IQ-CSRC prospective clinical Phase 1 study: "Can early QT assessment using exposure response analysis replace the thorough QT study?".
Darpo B; Sarapa N; Garnett C; Benson C; Dota C; Ferber G; Jarugula V; Johannesen L; Keirns J; Krudys K; Ortemann-Renon C; Riley S; Rogers-Subramaniam D; Stockbridge N
Ann Noninvasive Electrocardiol; 2014 Jan; 19(1):70-81. PubMed ID: 24372708
[TBL] [Abstract][Full Text] [Related]
5. Assay sensitivity in "Hybrid thorough QT/QTc (TQT)" study.
Huang DP; Chen J; Dang Q; Tsong Y
J Biopharm Stat; 2019; 29(2):378-384. PubMed ID: 30346877
[TBL] [Abstract][Full Text] [Related]
6. Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.
Matz J; Graff C; Vainio PJ; Kallio A; Højer AM; Struijk JJ; Kanters JK; Andersen MP; Toft E
Clin Drug Investig; 2011 Nov; 31(11):799-811. PubMed ID: 21967071
[TBL] [Abstract][Full Text] [Related]
7. Results from a Joined Prospective Study to Evaluate the Sensitivity of the In Vivo Dog QT Assay in Line with the ICH E14/S7B Q&A Best Practices.
Bétat AM; Delaunois A; Delpy E; Loiseau M; Maurin A; Poizat G; Possémé C; Weinelt F; Drieu la Rochelle C; Martel E; Valentin JP
Clin Pharmacol Ther; 2024 Jul; 116(1):106-116. PubMed ID: 38709223
[TBL] [Abstract][Full Text] [Related]
8. Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective.
Vargas HM; Rolf MG; Wisialowski TA; Achanzar W; Bahinski A; Bass A; Benson CT; Chaudhary KW; Couvreur N; Dota C; Engwall MJ; Michael Foley C; Gallacher D; Greiter-Wilke A; Guillon JM; Guth B; Himmel HM; Hegele-Hartung C; Ito M; Jenkinson S; Chiba K; Lagrutta A; Levesque P; Martel E; Okai Y; Peri R; Pointon A; Qu Y; Teisman A; Traebert M; Yoshinaga T; Gintant GA; Leishman DJ; Valentin JP
Clin Pharmacol Ther; 2021 Feb; 109(2):310-318. PubMed ID: 32866317
[TBL] [Abstract][Full Text] [Related]
9. Early QT assessment--how can our confidence in the data be improved?
Darpo B; Garnett C
Br J Clin Pharmacol; 2013 Nov; 76(5):642-8. PubMed ID: 23278510
[TBL] [Abstract][Full Text] [Related]
10. Challenges in implementing and obtaining acceptance for J-Tpeak assessment as the clinical component of CiPA.
Darpo B; Couderc JP
J Pharmacol Toxicol Methods; 2018; 93():75-79. PubMed ID: 29879475
[TBL] [Abstract][Full Text] [Related]
11. Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase.
Darpo B; Benson C; Dota C; Ferber G; Garnett C; Green CL; Jarugula V; Johannesen L; Keirns J; Krudys K; Liu J; Ortemann-Renon C; Riley S; Sarapa N; Smith B; Stoltz RR; Zhou M; Stockbridge N
Clin Pharmacol Ther; 2015 Apr; 97(4):326-35. PubMed ID: 25670536
[TBL] [Abstract][Full Text] [Related]
12. Can Bias Evaluation Provide Protection Against False-Negative Results in QT Studies Without a Positive Control Using Exposure-Response Analysis?
Ferber G; Zhou M; Dota C; Garnett C; Keirns J; Malik M; Stockbridge N; Darpo B
J Clin Pharmacol; 2017 Jan; 57(1):85-95. PubMed ID: 27271102
[TBL] [Abstract][Full Text] [Related]
13. Can an early phase clinical pharmacology study replace a thorough QT study? Experience with a novel H3-receptor antagonist/inverse agonist.
Shah RR; Maison-Blanche P; Robert P; Denis E; Duvauchelle T
Eur J Clin Pharmacol; 2016 May; 72(5):533-43. PubMed ID: 26879827
[TBL] [Abstract][Full Text] [Related]
14. Do Studies Evaluating QT/QTc Interval Prolongation with Dietary Supplements Meet FDA Standards: A Systematic Review.
Nguyen TA; Kurian A; Leong J; Patel UM; Shah SA
J Diet Suppl; 2017 Jul; 14(4):467-477. PubMed ID: 27937000
[TBL] [Abstract][Full Text] [Related]
15. New in vitro model for proarrhythmia safety screening: IKs inhibition potentiates the QTc prolonging effect of IKr inhibitors in isolated guinea pig hearts.
Kui P; Orosz S; Takács H; Sarusi A; Csík N; Rárosi F; Csekő C; Varró A; Papp JG; Forster T; Farkas AS; Farkas A
J Pharmacol Toxicol Methods; 2016; 80():26-34. PubMed ID: 27063345
[TBL] [Abstract][Full Text] [Related]
16. Detection of QT prolongation using a novel electrocardiographic analysis algorithm applying intelligent automation: prospective blinded evaluation using the Cardiac Safety Research Consortium electrocardiographic database.
Green CL; Kligfield P; George S; Gussak I; Vajdic B; Sager P; Krucoff MW
Am Heart J; 2012 Mar; 163(3):365-71. PubMed ID: 22424006
[TBL] [Abstract][Full Text] [Related]
17. Should You Run a Dedicated TQT Study? Sponsor and Regulatory Considerations on Substitution Pathways to Assess QT Liability.
Lester RM; Engel C; van Haarst AD; Paglialunga S
Clin Pharmacol Ther; 2024 Jul; 116(1):42-51. PubMed ID: 38698592
[TBL] [Abstract][Full Text] [Related]
18. Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for the Treatment of Patients With Cushing Syndrome, Does Not Cause Prolongation of the Cardiac QT Interval.
Donegan DM; Pivonello R; Stigliano A; Lardo P; Kearney T; Mezősi E; Ghigo E; Giordano R; Mariash CN; Feelders RA; Donaldson K; Darpo B; Xue H; Custodio JM; Hand AL; Moraitis AG
Endocr Pract; 2024 Jan; 30(1):11-18. PubMed ID: 37805100
[TBL] [Abstract][Full Text] [Related]
19. ECG Evaluation as Part of the Clinical Pharmacology Strategy in the Development of New Drugs: A Review of Current Practices and Opportunities Based on Five Case Studies.
Darpo B; Borin M; Ferber G; Galluppi GR; Hopkins SC; Landry I; Lo A; Rege B; Reyderman L; Sun L; Watanabe T; Xue H; Yasuda S
J Clin Pharmacol; 2022 Dec; 62(12):1480-1500. PubMed ID: 35665514
[TBL] [Abstract][Full Text] [Related]
20. Effects of moxifloxacin on the proarrhythmic surrogate markers in healthy Filipino subjects: Exposure-response modeling using ECG data of thorough QT/QTc study.
Matsukura S; Nakamura Y; Hoshiai K; Hayashi T; Koga T; Goto A; Chiba K; Lubna NJ; Hagiwara-Nagasawa M; Izumi-Nakaseko H; Ando K; Naito AT; Sugiyama A
J Pharmacol Sci; 2018 Apr; 136(4):234-241. PubMed ID: 29627227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
